This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Peptide-nanoparticle conjugates (like TAT-gold nanoparticles and RGD-polymer systems) overcome peptide drug limitations by improving blood-brain barrier crossing, stability, and targeted delivery for neurodegenerative diseases.
Why it matters
Peptide drugs for brain diseases are limited by rapid breakdown and poor brain penetration. Nanoparticle conjugation solves both problems.
The numbers in context
Peptides <45 amino acids; examples: TAT-functionalized gold NPs, RGD-decorated polymeric systems; improved BBB crossing in preclinical models.
How the study worked
Narrative review of bionanoconjugate strategies for neurodegenerative disease therapy.
Who was studied
N/A
What this study cannot tell us
Most evidence preclinical. BBB crossing in humans may differ from animal models. Manufacturing complexity. Regulatory hurdles for nanomedicines.
Read the original research
Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next-Generation Therapies.
Pharmaceutical research, 42(12), 2379-2404
Citation
Ranjitha, V R; Kumar, Anil; Kaalappa, Prashantha. (2025). Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next-Generation Therapies.. Pharmaceutical research, 42(12), 2379-2404. https://doi.org/10.1007/s11095-025-03941-0